Biocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration
The collaboration also includes a plan to evaluate the feasibility of developing best-in-class products based on the integration of
"We are excited to expand our work with Thermo Fisher by deriving synergies from the combination of cutting-edge technologies and services from both companies," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, the success of the collaboration with Thermo Fisher including our ability to develop best-in-class products and services, our ability to undertake joint commercialization activities with Thermo Fisher, our ability to validate Thermo Fisher's Oncomine™ NGS liquid biopsy panels, our ability to jointly pursue commercial opportunities with Thermo Fisher, and our ability to achieve synergies from the collaboration, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-and-thermo-fisher-scientific-enter-into-technology-and-commercial-collaboration-300620758.html
SOURCE
Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100; Media Contact: Trevelino/Keller, Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109